Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 47
Filtrar
Mais filtros

Medicinas Complementares
Intervalo de ano de publicação
1.
EMBO Mol Med ; 15(2): e16525, 2023 02 08.
Artigo em Inglês | MEDLINE | ID: mdl-36645044

RESUMO

Iron accumulation causes cell death and disrupts tissue functions, which necessitates chelation therapy to reduce iron overload. However, clinical utilization of deferoxamine (DFO), an iron chelator, has been documented to give rise to systemic adverse effects, including ocular toxicity. This study provided the pathogenic and molecular basis for DFO-related retinopathy and identified retinal pigment epithelium (RPE) as the target tissue in DFO-related retinopathy. Our modeling demonstrated the susceptibility of RPE to DFO compared with the neuroretina. Intriguingly, we established upregulation of hypoxia inducible factor (HIF) 2α and mitochondrial deficit as the most prominent pathogenesis underlying the RPE atrophy. Moreover, suppressing hyperactivity of HIF2α and preserving mitochondrial dysfunction by α-ketoglutarate (AKG) protects the RPE against lesions both in vitro and in vivo. This supported our observation that AKG supplementation alleviates visual impairment in a patient undergoing DFO-chelation therapy. Overall, our study established a significant role of iron deficiency in initiating DFO-related RPE atrophy. Inhibiting HIF2α and rescuing mitochondrial function by AKG protect RPE cells and can potentially ameliorate patients' visual function.


Assuntos
Quelantes de Ferro , Doenças Retinianas , Humanos , Quelantes de Ferro/efeitos adversos , Morte Celular , Atrofia/induzido quimicamente
2.
Biomed Pharmacother ; 139: 111590, 2021 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-33865017

RESUMO

Muscle atrophy and weakness are the adverse effects of long-term or high dose usage of glucocorticoids. In the present study, we explored the effects of fucoxanthin (10 µM) on dexamethasone (10 µM)-induced atrophy in C2C12 myotubes and investigated its underlying mechanisms. The diameter of myotubes was observed under a light microscope, and the expression of myosin heavy chain (MyHC), proteolysis-related, autophagy-related, apoptosis-related, and mitochondria-related proteins was analyzed by western blots or immunoprecipitation. Fucoxanthin alleviates dexamethasone-induced muscle atrophy in C2C12 myotubes, indicated by increased myotubes diameter and expression of MyHC, decreased expression of muscle atrophy F-box (Atrogin-1) and muscle ring finger 1 (MuRF1). Through activating SIRT1, fucoxanthin inhibits forkhead box O (FoxO) transcriptional activity to reduce protein degradation, induces autophagy to enhance degraded protein clearance, promotes mitochondrial function and diminishes apoptosis. In conclusion, we identified fucoxanthin ameliorates dexamethasone induced C2C12 myotubes atrophy through SIRT1 activation.


Assuntos
Atrofia/induzido quimicamente , Atrofia/tratamento farmacológico , Dexametasona , Fibras Musculares Esqueléticas/efeitos dos fármacos , Xantofilas/farmacologia , Animais , Apoptose/efeitos dos fármacos , Atrofia/genética , Atrofia/metabolismo , Autofagia/efeitos dos fármacos , Linhagem Celular , Sobrevivência Celular/efeitos dos fármacos , Proteína Forkhead Box O3/metabolismo , Camundongos , Fibras Musculares Esqueléticas/patologia , Proteínas Proto-Oncogênicas c-akt/metabolismo , Sirtuína 1/genética , Sirtuína 1/metabolismo
3.
Am J Chin Med ; 48(3): 631-650, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32329640

RESUMO

The loss of skeletal muscle mass and function is a serious consequence of chronic diseases and aging. BST204 is a purified ginseng (the root of Panax ginseng) extract that has been processed using ginsenoside-ß-glucosidase and acid hydrolysis to enrich ginsenosides Rg3 and Rh2 from the crude ginseng. BST204 has a broad range of health benefits, but its effects and mechanism on muscle atrophy are currently unknown. In this study, we have examined the effects and underlying mechanisms of BST204 on myotube formation and myotube atrophy induced by tumor necrosis factor-α (TNF-α). BST204 promotes myogenic differentiation and multinucleated myotube formation through Akt activation. BST204 prevents myotube atrophy induced by TNF-α through the activation of Akt/mTOR signaling and down-regulation of muscle-specific ubiquitin ligases, MuRF1, and Atrogin-1. Furthermore, BST204 treatment in atrophic myotubes suppresses mitochondrial reactive oxygen species (ROS) production and regulates mitochondrial transcription factors such as NRF1 and Tfam, through enhancing the activity and expression of peroxisome proliferator-activated receptor-γ coactivator1α (PGC1α). Collectively, our findings indicate that BST204 improves myotube formation and PGC1α-mediated mitochondrial function, suggesting that BST204 is a potential therapeutic or neutraceutical remedy to intervene muscle weakness and atrophy.


Assuntos
Desenvolvimento Muscular/efeitos dos fármacos , Fibras Musculares Esqueléticas/efeitos dos fármacos , Panax/química , Fitoterapia , Extratos Vegetais/farmacologia , Extratos Vegetais/uso terapêutico , Animais , Atrofia/induzido quimicamente , Atrofia/tratamento farmacológico , Humanos , Mitocôndrias Musculares/metabolismo , Fibras Musculares Esqueléticas/metabolismo , Fibras Musculares Esqueléticas/patologia , Fibras Musculares Esqueléticas/fisiologia , Fator 1 Nuclear Respiratório/metabolismo , Coativador 1-alfa do Receptor gama Ativado por Proliferador de Peroxissomo/metabolismo , Extratos Vegetais/isolamento & purificação , Proteínas Proto-Oncogênicas c-akt/metabolismo , Espécies Reativas de Oxigênio/metabolismo , Transdução de Sinais/efeitos dos fármacos , Estimulação Química , Serina-Treonina Quinases TOR/metabolismo , Fator de Necrose Tumoral alfa
4.
J Chem Neuroanat ; 102: 101706, 2019 12.
Artigo em Inglês | MEDLINE | ID: mdl-31669431

RESUMO

BACKGROUND: Cerebellar ataxias comprise a group of terminal illnesses with ataxia as the main symptom. Curcumin as a yellow polyphenol was extracted from the rhizome ofCurcuma longa. Owing to its antioxidant, anti-inflammatory, anti-fibrotic and anti-tumor features, curcumin is considered as a potential therapeutic agent. AIM: In this study, we aim to investigate the neuroprotective effects of oral administration of curcumin on a rat model of cerebellar ataxia induced by neurotoxin 3-acetylpyridine. METHODS: The animals were randomly separated into three groups (control, 3-acetylpyridine, and curcumin + 3-acetylpyridine). Next, motor performance and muscle electromyography activity were assessed. Then, in the molecular part of the study, the anti-apoptotic role of curcumin in cerebellar ataxia and its relationship to protection of Purkinje cells were investigated. RESULTS: Curcumin treatment improved motor coordination and muscular activity, reduced cleaved caspase-3, and increased glutathione level in 3-AP-lesioned rats as well as total volumes of cerebellar granular and molecular layers. CONCLUSION: the present study implies that curcumin might have neuroprotective effects to counteract neurotoxicity of 3-AP-induced ataxia.


Assuntos
Atrofia/tratamento farmacológico , Ataxia Cerebelar/tratamento farmacológico , Cerebelo/efeitos dos fármacos , Curcumina/uso terapêutico , Atividade Motora/efeitos dos fármacos , Fármacos Neuroprotetores/uso terapêutico , Células de Purkinje/efeitos dos fármacos , Animais , Atrofia/induzido quimicamente , Atrofia/patologia , Ataxia Cerebelar/induzido quimicamente , Ataxia Cerebelar/patologia , Cerebelo/patologia , Curcumina/farmacologia , Modelos Animais de Doenças , Eletromiografia , Masculino , Fármacos Neuroprotetores/farmacologia , Células de Purkinje/patologia , Piridinas , Ratos , Ratos Sprague-Dawley
5.
Ann Surg Oncol ; 26(12): 4100-4107, 2019 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-31440929

RESUMO

BACKGROUND: The purpose of this study was to investigate the incidence, origin, and clinical significance of liver atrophy during chemotherapy for colorectal cancer. METHODS: This study included 103 patients who underwent chemotherapy before resection for colorectal liver metastases (training set) and 171 patients who underwent adjuvant or first-line chemotherapy without liver resection (validation set). A greater than 10% decrease (atrophy) or increase (hypertrophy) of the liver volume from the baseline was defined as a significant change. RESULTS: In the training set, the numbers of patients who developed atrophy, no change of volume, and hypertrophy of the liver after chemotherapy were 15 (14.6%), 73 (70.9%), and 15 (14.6%), respectively. Liver atrophy was associated with impaired hepatic function, and the postoperative morbidity rate and refractory ascites/pleural effusion were higher in the patients with liver atrophy than those without (60.0% vs. 31.8%, P = 0.045 and 46.7% vs. 8.0%, P < 0.001, respectively). Histopathological examination revealed a strong association between sinusoidal injury and liver atrophy (P < 0.001). The cumulative incidence of liver atrophy increased with increasing duration of chemotherapy, whereas the incidence of liver atrophy was less frequent in patients who had received bevacizumab than those who had not in both the training set (odds ratio [OR], 0.13; P = 0.001) and the validation set (OR, 0.31; P = 0.007). CONCLUSIONS: Liver atrophy is associated with impaired hepatic functional reserve and observed at an increasing frequency as the duration of chemotherapy increases with frequent histopathological evidence of sinusoidal injury in the liver. Bevacizumab may protect against the development of liver atrophy.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Atrofia/patologia , Doença Hepática Induzida por Substâncias e Drogas/patologia , Neoplasias Colorretais/tratamento farmacológico , Neoplasias Hepáticas/tratamento farmacológico , Complicações Pós-Operatórias , Adulto , Idoso , Idoso de 80 Anos ou mais , Atrofia/induzido quimicamente , Bevacizumab/administração & dosagem , Doença Hepática Induzida por Substâncias e Drogas/etiologia , Neoplasias Colorretais/patologia , Feminino , Fluoruracila/administração & dosagem , Seguimentos , Humanos , Leucovorina/administração & dosagem , Neoplasias Hepáticas/secundário , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Retrospectivos , Taxa de Sobrevida
6.
J Coll Physicians Surg Pak ; 28(9): 659-662, 2018 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-30158028

RESUMO

OBJECTIVE: To determine the effect of commercial green tea on ibuprofen-induced glomerular atrophy in kidney of adult rat by using transvertical glomerular diameter as the determining parameter. STUDY DESIGN: Laboratory-based experimental study. PLACE AND DURATION OF STUDY: Department of Anatomy, Army Medical College Rawalpindi in collaboration with National Institute of Health (NIH) Islamabad from December 2016 to January 2017. METHODOLOGY: Thirty Sprague-dawley rats, males and females, were selected and divided into three groups. Each group comprised of 10 animals. Group A was used as control. Group B was given ibuprofen 120 mg/kg bodyweight/day. Group C received extract of Lipton green tea 1 ml/100 mg bodyweight/day in addition to ibuprofen 120 mg/kg. The dose was administered once daily for a period of 9 weeks. Animals were sacrificed 24 hours after administration of last dose. Kidney tissue was processed and stained with H&E. Routine histological study was performed. Change in transvertical glomerular diameter was taken as the defining parameter for determining glomerular atrophy. SPSS version 22 was the tool used for statistical analysis. P-value <0.05 was considered significant. RESULTS: Transvertical glomerular diameter (TVGD) was significantly decreased in both experimental groups B (76.15 +1.85 µm) and C (89.59 +1.87 µm) in comparison with control group A (94.27 +1.82 µm). However, the difference in TVGD between both experimental groups was also significant, asserting the ameliorative effect of green tea against glomerular damage. CONCLUSION: Ibuprofen caused glomerular atrophy but administration of green tea along with ibuprofen protected against significant reduction in glomerular diameter, thus preventing atrophy.


Assuntos
Antioxidantes/uso terapêutico , Atrofia/induzido quimicamente , Ibuprofeno/efeitos adversos , Rim/efeitos dos fármacos , Substâncias Protetoras/administração & dosagem , Chá , Adulto , Animais , Antioxidantes/administração & dosagem , Humanos , Ratos
7.
J Ethnopharmacol ; 224: 441-450, 2018 Oct 05.
Artigo em Inglês | MEDLINE | ID: mdl-29920360

RESUMO

ETHNOPHARMACOLOGICAL RELEVANCE: Traditional herbal formula Gyejibokryeong-hwan (GJBRH; Guizhifuling-wan, Keishibukuryo-gan) consisting five medicinal herbs has been used to treat uterine disorders, gynecological diseases and blood stasis syndrome in Asia. AIM OF THE STUDY: We evaluated the safety of GJBRH in Crl:CD Sprague-Dawley (SD) rats over a period of 13 weeks. MATERIALS AND METHODS: To confirm the stability of the components of GJBRH, we analyzed the component contents in GJBRH at different storage periods, using high-performance liquid chromatography. Male and female SD rats were orally administered with GJBRH at doses of 0, 1000, 2000 and 5000 mg/kg/day for 13 weeks and assessed after a 4-week recovery period. Mortality, changes in body weight and food consumption, organ weights, hematology and serum biochemistry were monitored during the experimental period, along with clinical observations, ophthalmological examinations, urinalysis and histopathology. RESULTS: There were no significant differences among the eight marker compounds in GJBRH according to storage period. No significant GJBRH-treatment-related toxicological changes were observed in mortality or ophthalmological examinations in either sex. However, soft feces were observed in the male 5000 mg/kg/day group. In addition, there were significant changes in body weight and food consumption in both male and female rats treated with GJBRH at a dose of 5000 mg/kg/day. In the hematological examinations, we found a significant increase in white blood cells, neutrophils and fibrinogen in the 5000 mg/kg/day groups. In the urinalysis, a decrease in the total protein and albumin and an increase in the ovalbumin/globulin ratio were observed in both male and female rats treated with GJBRH at a dose of 5000 mg/kg/day. Histopathological examinations revealed erosion/ulcers and dilated glands in the stomachs of males from the 5000 mg/kg/day group, and squamous cell hyperplasia and epithelial atrophy was observed in the stomachs of both male and female rats treated with GJBRH at a dose of 5000 mg/kg/day. CONCLUSION: The no-observed-adverse-effect level (NOAEL) was 2000 mg/kg/day for both sexes.


Assuntos
Medicamentos de Ervas Chinesas/toxicidade , Animais , Atrofia/induzido quimicamente , Contagem de Células Sanguíneas , Peso Corporal/efeitos dos fármacos , Medula Óssea/efeitos dos fármacos , Medula Óssea/patologia , Medicamentos de Ervas Chinesas/análise , Ingestão de Alimentos/efeitos dos fármacos , Células Epiteliais/efeitos dos fármacos , Células Epiteliais/patologia , Feminino , Hiperplasia/induzido quimicamente , Fígado/efeitos dos fármacos , Fígado/patologia , Masculino , Nível de Efeito Adverso não Observado , Tamanho do Órgão/efeitos dos fármacos , Compostos Fitoquímicos/análise , Compostos Fitoquímicos/toxicidade , Ratos Sprague-Dawley , Baço/efeitos dos fármacos , Baço/patologia , Estômago/efeitos dos fármacos , Estômago/patologia , Testes de Toxicidade Subcrônica
8.
BMB Rep ; 51(1): 39-44, 2018 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-29301606

RESUMO

Exchange protein directly activated by cAMP (Epac) 2a-knockout (KO) mice exhibit accelerated diet-induced obesity and are resistant to leptin-mediated adipostatic signaling from the hypothalamus to adipose tissue, with sustained food intake. However, the impact of Epac2a deficiency on hypothalamic regulation of sympathetic nervous activity (SNA) has not been elucidated. This study was performed to elucidate the response of Epac2a-KO mice to dexamethasone-induced muscle atrophy and acute cold stress. Compared to age-matched wild-type mice, Epac2a-KO mice showed higher energy expenditures and expression of myogenin and uncoupling protein-1 in skeletal muscle (SM) and brown adipose tissue (BAT), respectively. Epac2a-KO mice exhibited greater endurance to dexamethasone and cold stress. In wild-type mice, exogenous leptin mimicked the responses observed in Epac2a-KO mice. This suggests that leptin-mediated hypothalamic signaling toward SNA appears to be intact in these mice. Hence, the potentiated responses of SM and BAT may be due to their high plasma leptin levels. [BMB Reports 2018; 51(1): 39-44].


Assuntos
Dexametasona/farmacologia , Fatores de Troca do Nucleotídeo Guanina/genética , Fatores de Troca do Nucleotídeo Guanina/metabolismo , Tecido Adiposo Marrom/metabolismo , Animais , Atrofia/induzido quimicamente , Atrofia/genética , Atrofia/metabolismo , Resposta ao Choque Frio , Hipotálamo/metabolismo , Leptina/metabolismo , Camundongos , Camundongos Knockout , Músculo Esquelético/efeitos dos fármacos , Músculo Esquelético/metabolismo , Miogenina/metabolismo , Obesidade/metabolismo , Transdução de Sinais/efeitos dos fármacos , Sistema Nervoso Simpático/efeitos dos fármacos , Sistema Nervoso Simpático/fisiologia , Proteína Desacopladora 1/metabolismo
9.
J Cell Mol Med ; 22(3): 1562-1573, 2018 03.
Artigo em Inglês | MEDLINE | ID: mdl-29105957

RESUMO

Enterocyte apoptosis induced by lipid emulsions is a key cause of intestinal atrophy under total parenteral nutrition (TPN) support, and our previous work demonstrated that olive oil lipid emulsion (OOLE) could induce enterocyte apoptosis via CUGBP, Elav-like family member 1 (CELF1)/ apoptosis-inducing factor (AIF) pathway. As TPN-associated complications are partially related to choline deficiency, we aimed to address whether choline supplementation could attenuate OOLE-induced enterocyte apoptosis. Herein we present evidence that supplementary choline exhibits protective effect against OOLE-induced enterocyte apoptosis both in vivo and in vitro. In a rat model of TPN, substantial reduction in apoptotic rate along with decreased expression of CELF1 was observed when supplementary choline was added to OOLE. In cultured Caco-2 cells, supplementary choline attenuated OOLE-induced apoptosis and mitochondria dysfunction by suppressing CELF1/AIF pathway. Compared to OOLE alone, the expression of CELF1 and AIF was significantly decreased by supplementary choline, whereas the expression of Bcl-2 was evidently increased. No obvious alterations were observed in Bax expression and caspase-3 activation. Mechanistically, supplementary choline repressed the expression of CELF1 by increasing the recruitment of CELF1 mRNA to processing bodies, thus resulting in suppression of its protein translation. Taken together, our data suggest that supplementary choline exhibits effective protection against OOLE-induced enterocyte apoptosis, and thus, it has the potential to be used for the prevention and treatment of TPN-induced intestinal atrophy.


Assuntos
Fator de Indução de Apoptose/genética , Atrofia/prevenção & controle , Proteínas CELF1/genética , Deficiência de Colina/prevenção & controle , Colina/administração & dosagem , Azeite de Oliva/efeitos adversos , Nutrição Parenteral Total/efeitos adversos , Animais , Apoptose/efeitos dos fármacos , Apoptose/genética , Fator de Indução de Apoptose/metabolismo , Atrofia/induzido quimicamente , Atrofia/genética , Atrofia/fisiopatologia , Proteínas CELF1/metabolismo , Células CACO-2 , Caspase 3/genética , Caspase 3/metabolismo , Deficiência de Colina/genética , Deficiência de Colina/fisiopatologia , Modelos Animais de Doenças , Emulsões , Enterócitos/efeitos dos fármacos , Enterócitos/metabolismo , Enterócitos/patologia , Regulação da Expressão Gênica , Humanos , Intestinos/efeitos dos fármacos , Intestinos/fisiopatologia , Masculino , Mitocôndrias/efeitos dos fármacos , Mitocôndrias/metabolismo , Azeite de Oliva/administração & dosagem , Proteínas Proto-Oncogênicas c-bcl-2/genética , Proteínas Proto-Oncogênicas c-bcl-2/metabolismo , Ratos , Ratos Sprague-Dawley , Transdução de Sinais , Proteína X Associada a bcl-2/genética , Proteína X Associada a bcl-2/metabolismo
10.
Dig Liver Dis ; 49(8): 878-882, 2017 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-28396103

RESUMO

BACKGROUND: To date, potential coeliac disease (PCD) occurring in adults remains an almost unexplored condition. AIMS: To explore the prognostic role of Marsh grade in adult PCD patients, and to evaluate the effects of gluten-containing diet (GCD) in asymptomatic PCD patients. METHODS: We retrospectively evaluated all consecutive adult PCD patients followed-up for at least 6 years. Patients were divided into: Group A (patients with Marsh 0 histology) and Group B (Marsh 1 patients). Symptomatic patients were started gluten-free diet (GFD), while asymptomatic subjects were kept on GCD and were followed-up. RESULTS: 56 PCD patients were enrolled (21 in Group A and 35 in Group B). Forty-three patients were symptomatic and started GFD. Of these, none of 15 patients in Group A and 8 of 28 patients in Group B developed immune-mediated disorders (IMD) during follow-up (P=0.03; OR=4.2). The 13 asymptomatic PCD patients were kept on GCD. During the follow-up, 9 patients developed CD-related symptoms, 6 villous atrophy and 8 IMD. At the end, patients kept on GCD were at higher risk of developing IMD than those following a GFD (61% vs 18%, P=0.03, OR=3.3). CONCLUSIONS: Although PCD with normal mucosa seems to be a milder disease, the continuation of GCD places patients at a high risk of developing villous atrophy and IMD compared to commencement of GFD. Adult PCD patients should start GFD even if not symptomatic.


Assuntos
Doença Celíaca/dietoterapia , Dieta Livre de Glúten , Adolescente , Adulto , Atrofia/induzido quimicamente , Doença Celíaca/patologia , Suplementos Nutricionais , Feminino , Seguimentos , Humanos , Mucosa Intestinal/patologia , Itália , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Retrospectivos , Adulto Jovem
11.
JAMA Neurol ; 73(6): 721-32, 2016 06 01.
Artigo em Inglês | MEDLINE | ID: mdl-27088965

RESUMO

IMPORTANCE: The use of anticholinergic (AC) medication is linked to cognitive impairment and an increased risk of dementia. To our knowledge, this is the first study to investigate the association between AC medication use and neuroimaging biomarkers of brain metabolism and atrophy as a proxy for understanding the underlying biology of the clinical effects of AC medications. OBJECTIVE: To assess the association between AC medication use and cognition, glucose metabolism, and brain atrophy in cognitively normal older adults from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Indiana Memory and Aging Study (IMAS). DESIGN, SETTING, AND PARTICIPANTS: The ADNI and IMAS are longitudinal studies with cognitive, neuroimaging, and other data collected at regular intervals in clinical and academic research settings. For the participants in the ADNI, visits are repeated 3, 6, and 12 months after the baseline visit and then annually. For the participants in the IMAS, visits are repeated every 18 months after the baseline visit (402 cognitively normal older adults in the ADNI and 49 cognitively normal older adults in the IMAS were included in the present analysis). Participants were either taking (hereafter referred to as the AC+ participants [52 from the ADNI and 8 from the IMAS]) or not taking (hereafter referred to as the AC- participants [350 from the ADNI and 41 from the IMAS]) at least 1 medication with medium or high AC activity. Data analysis for this study was performed in November 2015. MAIN OUTCOMES AND MEASURES: Cognitive scores, mean fludeoxyglucose F 18 standardized uptake value ratio (participants from the ADNI only), and brain atrophy measures from structural magnetic resonance imaging were compared between AC+ participants and AC- participants after adjusting for potential confounders. The total AC burden score was calculated and was related to target measures. The association of AC use and longitudinal clinical decline (mean [SD] follow-up period, 32.1 [24.7] months [range, 6-108 months]) was examined using Cox regression. RESULTS: The 52 AC+ participants (mean [SD] age, 73.3 [6.6] years) from the ADNI showed lower mean scores on Weschler Memory Scale-Revised Logical Memory Immediate Recall (raw mean scores: 13.27 for AC+ participants and 14.16 for AC- participants; P = .04) and the Trail Making Test Part B (raw mean scores: 97.85 seconds for AC+ participants and 82.61 seconds for AC- participants; P = .04) and a lower executive function composite score (raw mean scores: 0.58 for AC+ participants and 0.78 for AC- participants; P = .04) than the 350 AC- participants (mean [SD] age, 73.3 [5.8] years) from the ADNI. Reduced total cortical volume and temporal lobe cortical thickness and greater lateral ventricle and inferior lateral ventricle volumes were seen in the AC+ participants relative to the AC- participants. CONCLUSIONS AND RELEVANCE: The use of AC medication was associated with increased brain atrophy and dysfunction and clinical decline. Thus, use of AC medication among older adults should likely be discouraged if alternative therapies are available.


Assuntos
Encéfalo , Antagonistas Colinérgicos/efeitos adversos , Transtornos Cognitivos/induzido quimicamente , Idoso , Idoso de 80 Anos ou mais , Apolipoproteína E4/genética , Atrofia/induzido quimicamente , Atrofia/diagnóstico por imagem , Encéfalo/diagnóstico por imagem , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Encéfalo/patologia , Transtornos Cognitivos/diagnóstico por imagem , Transtornos Cognitivos/genética , Transtornos Cognitivos/patologia , Função Executiva/efeitos dos fármacos , Feminino , Fluordesoxiglucose F18/metabolismo , Humanos , Imageamento por Ressonância Magnética , Masculino , Transtornos da Memória/induzido quimicamente , Transtornos da Memória/diagnóstico por imagem , Testes Neuropsicológicos , Tomografia por Emissão de Pósitrons , Modelos de Riscos Proporcionais
12.
Sci Rep ; 5: 16078, 2015 Nov 06.
Artigo em Inglês | MEDLINE | ID: mdl-26542342

RESUMO

Oxaliplatin, a widely used chemotherapeutic agent, induces peripheral neuropathy that manifests itself as two distinct phases: acute cold hyperesthesia and chronic peripheral hypoesthesia/dysesthesia. The latter is a serious dose-limiting side effect that can often lead to withdrawal of treatment. We have developed a rat model expressing both phases and used the model to investigate the action of goshajinkigan (GJG), a traditional Japanese herbal medicine, which was reported to ameliorate oxaliplatin-induced neuropathy in a placebo-controlled double-blind randomized phase II study. In this study, neuropathy was induced by injection of oxaliplatin twice weekly for 8 wks. The maximum level of cold hyperesthesia was observed at 4 wks with heat hypoesthesia developing later. Microscopy studies revealed atrophy of axons of myelinated sciatic nerve fibers in oxaliplatin-treated rats at 8 wks. Co-administration of GJG ameliorated both abnormal sensations as well as histological damage to the sciatic nerve. A pharmacokinetic study revealed numerous neuroprotective components of GJG that are rapidly absorbed into the blood. GJG and some of its components attenuated the generation of oxaliplatin-induced reactive oxygen species, which is a possible mechanism of oxaliplatin-induced neurotoxicity. The present study provides a useful animal model for oxaliplatin-induced neurotoxicity as well as a promising prophylactic agent.


Assuntos
Medicamentos de Ervas Chinesas/farmacologia , Hipestesia/induzido quimicamente , Hipestesia/tratamento farmacológico , Fármacos Neuroprotetores/farmacologia , Compostos Organoplatínicos/efeitos adversos , Animais , Antineoplásicos/farmacologia , Atrofia/induzido quimicamente , Atrofia/tratamento farmacológico , Axônios/efeitos dos fármacos , Modelos Animais de Doenças , Gânglios Espinais/efeitos dos fármacos , Medicina Herbária/métodos , Masculino , Medicina Tradicional do Leste Asiático/métodos , Fibras Nervosas Mielinizadas/efeitos dos fármacos , Síndromes Neurotóxicas/tratamento farmacológico , Oxaliplatina , Doenças do Sistema Nervoso Periférico/induzido quimicamente , Doenças do Sistema Nervoso Periférico/tratamento farmacológico , Fitoterapia/métodos , Ratos , Ratos Sprague-Dawley
13.
J Nat Prod ; 78(9): 2297-300, 2015 Sep 25.
Artigo em Inglês | MEDLINE | ID: mdl-26299900

RESUMO

Axonal regeneration might contribute to the restoration of damaged neuronal networks and improvement of memory deficits in a murine Alzheimer's disease (AD) model. A search for axonal regenerative drugs was performed to discover novel therapeutic options for AD. In this study, an aqueous extract of Drynaria fortunei rhizomes reversed Aß25-35-induced axonal atrophy in cultured cortical neurons of mice. Bioassay-guided fractionation of this extract led to the isolation and identification of compounds 1-5. Among them, (2S)-neoeriocitrin (2) and caffeic acid 4-O-glucoside (4) showed significant axonal elongation effects on Aß25-35-induced atrophy.


Assuntos
Peptídeos beta-Amiloides/farmacologia , Medicamentos de Ervas Chinesas/isolamento & purificação , Medicamentos de Ervas Chinesas/farmacologia , Fragmentos de Peptídeos/farmacologia , Polypodiaceae/química , Doença de Alzheimer/tratamento farmacológico , Animais , Atrofia/induzido quimicamente , Axônios/efeitos dos fármacos , Medicamentos de Ervas Chinesas/química , Camundongos , Estrutura Molecular , Neurônios/efeitos dos fármacos , Rizoma/química
14.
J Cosmet Dermatol ; 14(4): E15-20, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26282056

RESUMO

BACKGROUND: One of the important and distressing cutaneous side effects of steroid therapy is skin atrophy, which has no definite and effective treatment. To the best of our knowledge, laser therapy for steroid-induced atrophic scars has not been investigated to date. OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of pulsed dye laser in the treatment of steroid-induced atrophic scars. METHODS: In this pilot study, 15 patients with at least one atrophic patch were treated with the 585-nm pulsed dye laser at 4-week interval sessions until achieving complete improvement or until patient were lost to follow-up. Clinical outcome was assessed via standard photographic method before each treatment session and after the final visit. An independent dermatologist evaluated the photographs. RESULT: All of the patients (13 females and two males) with 25-59 years of age experienced some degree of improvement, except one patient who withdrew from the treatment after three sessions. The treatment was well tolerated. CONCLUSION: The results of our study indicated that pulsed dye laser therapy could be employed as a new method in the treatment of steroid-induced atrophic scars. Pulsed dye laser might affect the lesions through inducing collagen deposition and production of more superficial dermal elastin as well as less unidirectional collagen in clusters.


Assuntos
Corticosteroides/efeitos adversos , Cicatriz/radioterapia , Lasers de Corante/uso terapêutico , Terapia com Luz de Baixa Intensidade , Pele/patologia , Pele/efeitos da radiação , Adulto , Atrofia/induzido quimicamente , Cicatriz/induzido quimicamente , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Projetos Piloto
15.
J Surg Res ; 199(2): 314-21, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26115806

RESUMO

BACKGROUND: Although the short-term adverse effects of sorafenib are well known, few data exist on long-term toxicity. The objective of the present study was to investigate the prevalence of pancreatic atrophy among a cohort of patients with hepatocellular carcinoma (HCC) who were treated with sorafenib for ≥2 y. METHODS: Between March 2007 and December 2013, 31 patients with HCC who were treated with sorafenib for ≥2 y were identified. The effect of pancreatic atrophy and enhancement on incidence of adverse events, tumor response, and overall survival (OS) were assessed. RESULTS: Thirty-one patients with HCC were treated with sorafenib for ≥2 y and met inclusion criteria; 11 patients (35.5%) were Barcelona-clinic liver cancer stage B, whereas 20 patients (64.5%) were Barcelona-clinic liver cancer stage C. Median duration of treatment with sorafenib was 35.2 mo. Pancreatic atrophy and a decrease in pancreatic enhancement occurred in 24 patients (77.4%) and 15 patients (48.4%), respectively. On the basis of the modified response evaluation criteria in solid tumors, four patients (12.9%) had a complete response, 10 patients (32.3%) had a partial response, and 17 patients (54.8%) had stable disease. Patients treated with sorafenib with pancreatic atrophy had a median OS of 49.4 mo (95% confidence interval, 41.2-57.5 mo) compared with 31.2 mo (95% confidence interval, 25.7-36.7 mo) among patients who did not develop pancreatic atrophy (P = 0.009). In contrast, survival was not associated with decreased versus normal enhancement of the pancreas (OS, 47.7 mo versus 41.7 mo, respectively; P = 0.739). CONCLUSIONS: Pancreatic atrophy occurred in many HCC patients after 2 y of treatment with sorafenib. Patients who experienced pancreatic atrophy had a better tumor response and OS.


Assuntos
Antineoplásicos/efeitos adversos , Carcinoma Hepatocelular/tratamento farmacológico , Neoplasias Hepáticas/tratamento farmacológico , Niacinamida/análogos & derivados , Pancreatopatias/induzido quimicamente , Compostos de Fenilureia/efeitos adversos , Idoso , Antineoplásicos/administração & dosagem , Atrofia/induzido quimicamente , Carcinoma Hepatocelular/mortalidade , China/epidemiologia , Estudos de Coortes , Feminino , Humanos , Neoplasias Hepáticas/mortalidade , Masculino , Pessoa de Meia-Idade , Niacinamida/administração & dosagem , Niacinamida/efeitos adversos , Pâncreas/patologia , Pancreatopatias/patologia , Compostos de Fenilureia/administração & dosagem , Sorafenibe , Resultado do Tratamento
16.
Toxicology ; 293(1-3): 78-88, 2012 Mar 11.
Artigo em Inglês | MEDLINE | ID: mdl-22239859

RESUMO

Copper is an essential trace element for human physiological processes. To evaluate the potential adverse health impact/immunotoxicological effects of this metal in situ due to over exposure, Swiss albino mice were treated (via intraperitoneal injections) with copper (II) chloride (copper chloride) at doses of 0, 5, or 7.5 mg copper chloride/kg body weight (b.w.) twice a week for 4 wk; these values were derived from LD50 studies using copper chloride doses that ranged from 0 to 40 mg/kg BW (2×/wk, for 4 wk). Copper treated mice evidenced immunotoxicity as indicated by dose-related decreases and increases, respectively, in thymic and splenic weights. Histomorphological changes evidenced in these organs were thymic atrophy, white pulp shrinkage in the spleen, and apoptosis of splenocytes and thymocytes; these observations were confirmed by microscopic analyses. Cell count analyses indicated that the proliferative functions of the splenocytes and thymocytes were also altered because of the copper exposures. Among both cell types from the copper treated hosts, flow cytometric analyses revealed a dose related increase in the percentages of cells in the Sub-G0/G1 state, indicative of apoptosis which was further confirmed by Annexin V binding assay. In addition, the copper treatments altered the expression of selected cell death related genes such as EndoG and Bax in a dose related manner. Immunohistochemical analyses revealed that there was also increased ubiquitin expression in both the cell types. In conclusion, these studies show that sublethal exposure to copper (as copper chloride) induces toxicity in the thymus and spleen, and increased Sub G0/G1 population among splenocytes and thymocytes that is mediated, in part, by the EndoG-Bax-ubiquitin pathway. This latter damage to these cells that reside in critical immune system organs are likely to be important contributing factors underlying the immunosuppression that has been documented by other investigators following acute high dose/chronic low-medium dose exposures to copper agents.


Assuntos
Pontos de Checagem do Ciclo Celular/efeitos dos fármacos , Morte Celular/efeitos dos fármacos , Cobre/intoxicação , Imunossupressores/intoxicação , Baço/efeitos dos fármacos , Timo/efeitos dos fármacos , Animais , Apoptose/efeitos dos fármacos , Atrofia/induzido quimicamente , Contagem de Células , Células Cultivadas , Cobre/administração & dosagem , Relação Dose-Resposta a Droga , Endodesoxirribonucleases/metabolismo , Imunossupressores/administração & dosagem , Injeções Intraperitoneais , Dose Letal Mediana , Camundongos , Tamanho do Órgão/efeitos dos fármacos , Distribuição Aleatória , Baço/imunologia , Baço/metabolismo , Baço/patologia , Timo/imunologia , Timo/metabolismo , Timo/patologia , Ubiquitina/metabolismo , Proteína X Associada a bcl-2/metabolismo
17.
Alcohol Clin Exp Res ; 36(5): 815-25, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22017419

RESUMO

BACKGROUND: The need of an animal model of alcoholism becomes apparent when we consider the genetic diversity of the human populations, an example being dopamine D2 receptor (DRD2) expression levels. Research suggests that low DRD2 availability is associated with alcohol abuse, while higher DRD2 levels may be protective against alcoholism. This study aims to establish whether (i) the ethanol-consuming mouse is a suitable model of alcohol-induced brain atrophy and (ii) DRD2 protect the brain against alcohol toxicity. METHODS: Adult Drd2+/+ and Drd2-/- mice drank either water or 20% ethanol solution for 6 months. At the end of the treatment period, the mice underwent magnetic resonance (MR) imaging under anesthesia. MR images were registered to a common space, and regions of interest were manually segmented. RESULTS: We found that chronic ethanol intake induced a decrease in the volume of the temporal and parietal cortices as well as the caudal thalamus in Drd2-/- mice. CONCLUSIONS: The result suggests that (i) normal DRD2 expression has a protective role against alcohol-induced brain atrophy and (ii) in the absence of Drd2 expression, prolonged ethanol intake reproduces a distinct feature of human brain pathology in alcoholism, the atrophy of the temporal and parietal cortices.


Assuntos
Depressores do Sistema Nervoso Central/toxicidade , Córtex Cerebral/efeitos dos fármacos , Etanol/toxicidade , Receptores de Dopamina D2/metabolismo , Tálamo/efeitos dos fármacos , Alcoolismo/patologia , Animais , Atrofia/induzido quimicamente , Atrofia/metabolismo , Córtex Cerebral/patologia , Imageamento por Ressonância Magnética , Masculino , Camundongos , Camundongos Knockout , Tamanho do Órgão/efeitos dos fármacos , Tálamo/patologia
18.
Reproduction ; 142(3): 417-25, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21670127

RESUMO

In seasonal breeders, reproduction is synchronised by day length via the pineal hormone melatonin. In short winter days (short day, SD), the Syrian hamster displays a complete gonadal atrophy together with a marked reduction in expression of kisspeptins (Kp), a family of potent hypothalamic stimulators of GNRH neurons. Both central and peripheral acute injections of Kp have been reported to activate the gonadotropic axis in mammals. The aim of this study was to determine if and how peripheral administration of Kp54 could restore gonadal function in photo-inhibited hamsters. Testicular activity of hamsters kept in SD was reactivated by two daily i.p. injections of Kp54 but not by chronic subcutaneous delivery of the same peptide via mini-pumps. Acute i.p. injection of Kp54-induced FOS (c-Fos) expression in a large number of GNRH neurons and pituitary gonadotrophs together with a strong increase in circulating testosterone. The activation of pituitary cells by Kp was inhibited by preadministration of the GNRH receptor antagonist acyline. Altogether, our results demonstrate that peripheral Kp54 activates the gonadotropic axis by stimulating GNRH release and indicate that an appropriate protocol of long-term systemic Kp administration can recrudesce a photo-inhibited reproductive axis.


Assuntos
Hormônio Liberador de Gonadotropina/metabolismo , Gônadas/efeitos dos fármacos , Kisspeptinas/farmacologia , Fotoperíodo , Testículo/efeitos dos fármacos , Administração Cutânea , Animais , Atrofia/induzido quimicamente , Cricetinae , Citoproteção/efeitos dos fármacos , Avaliação Pré-Clínica de Medicamentos , Gônadas/patologia , Humanos , Kisspeptinas/administração & dosagem , Masculino , Mesocricetus , Testículo/metabolismo , Testículo/patologia , Fatores de Tempo , Regulação para Cima
19.
J Nat Med ; 65(3-4): 417-23, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-21301979

RESUMO

Not only neuronal death but also neuritic atrophy and synaptic loss underlie the pathogenesis of Alzheimer's disease as direct causes of the memory deficit. Extracts of Siberian ginseng (the rhizome of Eleutherococcus senticosus) were shown to have protective effects on the regeneration of neurites and the reconstruction of synapses in rat cultured cortical neurons damaged by amyloid ß (Aß)(25-35), and eleutheroside B was one of the active constituents. In this study, a comprehensive evaluation of constituents was conducted to explore active components from Siberian ginseng which can protect against neuritic atrophy induced by Aß(25-35) in cultured rat cortical neurons. The ethyl acetate, n-butanol and water fractions from the methanol extract of Siberian ginseng showed protective effects against Aß-induced neuritic atrophy. Twelve compounds were isolated from the active fractions and identified. Among them, eleutheroside B, eleutheroside E and isofraxidin showed obvious protective effects against Aß(25-35)-induced atrophies of axons and dendrites at 1 and 10 µM.


Assuntos
Peptídeos beta-Amiloides/farmacologia , Atrofia/prevenção & controle , Córtex Cerebral/citologia , Eleutherococcus/química , Neuritos/efeitos dos fármacos , Neurônios/citologia , Neurônios/efeitos dos fármacos , Extratos Vegetais/farmacologia , Animais , Atrofia/induzido quimicamente , Axônios/efeitos dos fármacos , Benzaldeídos/química , Benzaldeídos/farmacologia , Células Cultivadas , Cumarínicos/química , Cumarínicos/farmacologia , Dendritos/efeitos dos fármacos , Ácidos Graxos/química , Ácidos Graxos/farmacologia , Feminino , Glucosídeos/química , Glucosídeos/farmacologia , Lignanas/química , Lignanas/farmacologia , Espectroscopia de Ressonância Magnética , Fenilpropionatos/química , Fenilpropionatos/farmacologia , Extratos Vegetais/química , Gravidez , Ratos , Ratos Sprague-Dawley , Sitosteroides/química , Sitosteroides/farmacologia , Espectrometria de Massas por Ionização por Electrospray , Estigmasterol/química , Estigmasterol/farmacologia
20.
Int Immunopharmacol ; 9(13-14): 1568-77, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19788936

RESUMO

Dexamethasone (DEX) is still the main choice for colitis, although the immunosuppressive side effects are still the troublesome problems to overcome. In our previous study, Rheum tanguticum polysaccharide (RTP), extracted from traditional Chinese medicine rhubarb, targeted mannose receptor, showed immunoregulatory effect on the balance of Th1 and Th2 polarization in colitis rats. For the present study, we hypothesized that RTP could regulate the immunosuppressive effects of DEX. Taking advantage of the colon delivery ability of the polysaccharide, we prepared the double emulsion of RTP microsphere containing DEX to investigate the potential immunoregulatory effects of RTP on DEX immunosuppression in TNBS-induced colitis in rats. As expected, DEX-RTP microsphere showed not only significant immunomodulatory effects, but also strong anti-inflammation. The microsphere balanced enteric bacteria disorder, decreased TLR4 activation and promoted the balance of Th1 and Th2 polarization, inhibited NF-kappaB activity. Especially, DEX-RTP showed significant colon injury reparation. DEX alone exhibited a strong anti-inflammatory effect by suppressing MPO activity, down-regulate NF-kappaB activity and Th1 cytokines production. However, DEX showed severe immunosuppressive effects. It aggravated the intestinal commensal bacteria disorder, induced thymus atrophy and the further imbalance of Th1/Th1 cytokine polarization. RTP showed significant immunoregulatory effects. A significant protection on the intestinal bacterial balance, TLR4 and NF-kappaB activation decreased, and Th1/Th2 cytokine production balance were showed in RTP. In conclusion, DEX-RTP microsphere delivered DEX directly to the colon avoiding the absorption at the upper intestinal tract and showed synergistic effects on colitis both from the strong anti-inflammatory effects of DEX and from the immunoregulation of RTP.


Assuntos
Colite/tratamento farmacológico , Colo/efeitos dos fármacos , Dexametasona/efeitos adversos , Imunossupressores/efeitos adversos , Nanocápsulas/administração & dosagem , Polissacarídeos/administração & dosagem , Rheum , Timo/efeitos dos fármacos , Animais , Atrofia/induzido quimicamente , Atrofia/prevenção & controle , Colite/induzido quimicamente , Colo/patologia , Dexametasona/administração & dosagem , Dexametasona/química , Imunomodulação , Imunossupressores/administração & dosagem , Imunossupressores/química , Enteropatias/induzido quimicamente , Enteropatias/prevenção & controle , Masculino , NF-kappa B/metabolismo , Nanocápsulas/química , Polissacarídeos/química , Ratos , Ratos Sprague-Dawley , Timo/patologia , Receptor 4 Toll-Like/metabolismo , Ácido Trinitrobenzenossulfônico/toxicidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA